Ben Turner

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Early onset cerebral amyloid angiopathy following childhood exposure to cadaveric dura

Gargi Banerjee, Matthew Adams, Zane Jaunmuktane et al. · Annals of Neurology · 2018 · 89 citations · Full text

Medicine, Neurology, Neurosurgery +13

Assessing emotional status following acquired brain injury: The clinical potential of the depression, anxiety and stress scales

Tamara Ownsworth, Trudi Little, Ben Turner et al. · Brain Injury · 2008 · 79 citations

Medicine, Behavioral Sciences, Psychology +15

Evidence of <i>Clostridium perfringens</i> epsilon toxin associated with multiple sclerosis

Sariqa Wagley, Monika Bokori-Brown, Helen Morcrette et al. · Multiple Sclerosis Journal · 2018 · 67 citations · Full text

Life Sciences, Immunology, Pathobiology +17